Keeping Track: Approvals For Phexxi, Kynombi; New Claims For Lynparza, Alunbrig, Tecentriq; Intercept May Miss NASH User Fee Date

 
• By Bridget Silverman and Brenda Sandburg
Keeping Track Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers